ArticleJournal of bone metabolism2026
Effects of Normocalcemic Hyperparathyroidism on Structural Bone Compromise: A Prospective Observational Cohort Study.
Article in Journal of bone metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNormocalcemic hyperparathyroidism (NCHPTH) is characterized by elevated serum parathyroid hormone (PTH) levels in the presence of normal serum calcium levels, with the exclusion of secondary causes. NCHPTH remains underdiagnosed and is often associated with structural compromise of bone, namely osteoporosis and fragility fractures. The purpose of this study was to perform a prospective observational cohort study investigating NCHPTH in our Metabolic Bone Disease Service (MBDS).
methodsBetween January 2022 and June 2024, 815 patients were referred to our MBDS with an International Classification of Diseases, Tenth Revision diagnosis code of osteoporosis. Each patient underwent dual energy X-ray absorptiometry, and when indicated, assays for serum calcium, ionized calcium, 25-hydroxy-vitamin D (25[OH]D), and PTH.
resultsNCHPTH was identified in 25 patients (3%), approximating one patient per month. Skeletal involvement was frequent in the NCHPTH cohort, with 72% presenting with a history of fragility fractures. Mean PTH levels were 130.8 pg/mL, while serum calcium and 25(OH)D levels remained within the normal range. We compared the prevalence of NCHPTH in our MBDS to other referral populations, finding an increased prevalence in our service, likely due to the high frequency of skeletal compromise in this population.
conclusionsThese results indicate that NCHPTH is not merely a biochemical phenomenon but is rather frequently associated with skeletal pathology. We conclude that reliance on serum calcium alone likely leads to underdiagnosis of NCHPTH, whereas routine PTH testing can facilitate earlier detection, allow for preventative interventions, and enhance secondary fracture prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.